Latest filings (excl ownership)
8-K
Entry into a Material Definitive Agreement
2 May 24
8-K
Regulation FD Disclosure
28 Mar 24
10-K
2023 FY
Annual report
27 Mar 24
8-K
Evofem Reports $18.2 million of Phexxi Net Product Sales in 2023
27 Mar 24
8-K
Entry into a Material Definitive Agreement
6 Mar 24
8-K
Evofem Biosciences Announces Strong Preliminary Results, Record Phexxi Net Sales for Fiscal 2023
1 Feb 24
8-K
Entry into a Material Definitive Agreement
31 Jan 24
8-K/A
Financial Statements and Exhibits
25 Jan 24
8-K
Entry into a Material Definitive Agreement
11 Jan 24
8-K
Entry into a Material Definitive Agreement
26 Dec 23
8-K
Entry into a Material Definitive Agreement
12 Dec 23
8-K
Entry into a Material Definitive Agreement
7 Dec 23
10-Q
2023 Q3
Quarterly report
14 Nov 23
8-K
Evofem Biosciences Announces Financial Results for the Third Quarter of 2023
14 Nov 23
8-K
Evofem Biosciences Announces Preliminary Results for the Third Quarter of 2023
24 Oct 23
D
$2.88 mm in debt / options / securities to be acquired, sold $2.88 mm, 14 investors
10 Oct 23
8-K
Entry into a Material Definitive Agreement
3 Oct 23
8-K
Evofem Announces Padagis Will Not Seek FDA Approval to Market a Generic Version of Phexxi Until Evofem’s Phexxi Patents Expire
27 Sep 23
8-K
Amendments to Articles of Incorporation or Bylaws
15 Sep 23
8-K
Entry into a Material Definitive Agreement
11 Sep 23
DEF 14A
Definitive proxy
29 Aug 23
8-K
Regulation FD Disclosure
28 Aug 23
PRER14A
Preliminary revised proxy
18 Aug 23
8-K/A
Entry into a Material Definitive Agreement
18 Aug 23
EFFECT
Notice of effectiveness
15 Aug 23
10-Q
2023 Q2
Quarterly report
14 Aug 23
8-K
Evofem Biosciences Announces Financial Results for the Second Quarter of 2023
14 Aug 23
424B3
Prospectus supplement
14 Aug 23
S-1/A
IPO registration (amended)
10 Aug 23
PRE 14A
Preliminary proxy
10 Aug 23
8-K
Entry into a Material Definitive Agreement
10 Aug 23
CORRESP
Correspondence with SEC
10 Aug 23
S-1/A
IPO registration (amended)
3 Aug 23
CORRESP
Correspondence with SEC
3 Aug 23
UPLOAD
Letter from SEC
19 Jul 23
8-K
Material Modifications to Rights of Security Holders
17 Jul 23
8-K
Entry into a Material Definitive Agreement
10 Jul 23
S-1
IPO registration
7 Jul 23
8-K
Submission of Matters to a Vote of Security Holders
20 Jun 23
10-Q
2023 Q1
Quarterly report
16 Jun 23
Latest ownership filings
SC 13G/A
CVI Investments, Inc.
14 Feb 24
4
Yan Zhang
12 Jan 24
4
Kim P. Kamdar
22 Dec 23
5
Justin J. File
8 May 23
4
SAUNDRA L PELLETIER
26 Apr 23
3
Yan Zhang
26 Apr 23
SC 13G/A
CVI Investments, Inc.
14 Feb 23
SC 13G/A
Cox Todd Stewart
10 Aug 22
3
Jenny C. Yip
8 Aug 22
SC 13G
Cox Todd Stewart
19 Jul 22
3
Katherine Cocca Atkinson
7 Jun 22
4
SAUNDRA L PELLETIER
31 May 22
4
Anthony Stephen O'Brien
6 May 22
4
Kim P. Kamdar
6 May 22
4
Colin Rutherford
6 May 22
4
Lisa Dale Rarick
6 May 22
4
Gillian Greer
6 May 22
4
Alexander A Fitzpatrick
23 Feb 22
4
Justin J. File
23 Feb 22
4
SAUNDRA L PELLETIER
23 Feb 22
SC 13G/A
CVI Investments, Inc.
14 Feb 22
4
Alexander A Fitzpatrick
4 Jan 22
4
Justin J. File
4 Jan 22
4
SAUNDRA L PELLETIER
4 Jan 22
4
Alexander A Fitzpatrick
20 Dec 21
4
Justin J. File
20 Dec 21
4
SAUNDRA L PELLETIER
20 Dec 21
SC 13G/A
MORGAN STANLEY
10 Sep 21
SC 13G/A
BlackRock Inc.
12 Jul 21
4
Russell Barrans
9 Jul 21
4
Kim P. Kamdar
21 Jun 21
4
Lisa Dale Rarick
14 Jun 21
4
Anthony Stephen O'Brien
14 Jun 21
4
Russell Barrans
11 Jun 21
4
Justin J. File
10 Jun 21
4
SAUNDRA L PELLETIER
10 Jun 21
4
Alexander A Fitzpatrick
10 Jun 21
SC 13G
MORGAN STANLEY
4 Jun 21
SC 13G
CVI Investments, Inc.
28 May 21
4
Alexander A Fitzpatrick
21 May 21